SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE L impact

Nuvectis Pharma to participate in upcoming investor conferences

Nuvectis Pharma said it will participate in upcoming investor conferences. The clinical-stage biopharmaceutical company focuses on complement-related conditions and oncology.

NVCT

Fort Lee, NJ, Sept.

03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc.

NASDAQ:NVCT ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that membe…